Regulatory compliance – Page 48

Uncontrolled document revisions during audit trail review – ALCOA+ gap analysis

Managing Uncontrolled Document Revisions During Audit Trail Review: An Actionable Playbook In the highly regulated pharmaceutical industry, the integrity of documentation is paramount. Uncontrolled document revisions during audit trail review…

Inspection readiness untested during WHO audit – evidence pack inspectors expect

Practical Playbook for Ensuring Inspection Readiness During WHO Audits In the pharmaceutical industry, the possibility of audits from the World Health Organization (WHO) can create significant anxiety regarding inspection readiness…

GDP errors in batch records during routine operations – GDP remediation CAPA

Mitigating GDP Errors in Batch Records: A Comprehensive Remediation CAPA Playbook In the highly regulated pharmaceutical sector, GDP (Good Documentation Practices) errors in batch records during routine operations can compromise…

Inspection responses delayed during remediation tracking – preventing escalation to warning letter

Resolving Delayed Inspection Responses During Remediation Tracking to Avoid Escalation In the pharmaceutical manufacturing landscape, the timely response during remediation tracking is critical to maintaining compliance and avoiding regulatory citations.…

GDP errors in batch records during record archival – evidence pack inspectors expect

Addressing GDP Errors in Batch Records during Archival: An Inspection-Ready Playbook In the pharmaceutical industry, ensuring the integrity and compliance of batch records is paramount. One critical area prone to…

Team unprepared for interviews during FDA/EMA inspection – inspection playbook and preparation strategy

Preparing Your Team for Successful Interviews During FDA and EMA Inspections In the highly regulated pharmaceutical industry, regulatory inspections are critical checkpoints to ensure compliance with Good Manufacturing Practices (GMP).…

GDP errors in batch records during audit trail review – ALCOA+ gap analysis

Addressing GDP Errors in Batch Records During Audit Trail Reviews Using ALCOA+ Gap Analysis GDP errors in batch records during audit trail review pose significant risks to pharmaceutical manufacturing’s integrity…

CAPA follow-up weak before regulatory inspection – CAPA closure verification

Addressing Deficiencies in CAPA Follow-Up Prior to Regulatory Inspections In pharmaceutical manufacturing, efficient Corrective and Preventive Actions (CAPA) are crucial for maintaining compliance with Good Manufacturing Practices (GMP) and preparing…

Data attribution unclear during routine operations – evidence pack inspectors expect

Navigating Data Attribution Issues during Routine Operations in Pharmaceutical Manufacturing In the complex landscape of pharmaceutical manufacturing, ensuring data attribution clarity is critical. Without it, organizations expose themselves to significant…

Inspection readiness untested during FDA/EMA inspection – inspection playbook and preparation strategy

Practical Guide to Enhancing Inspection Readiness for FDA and EMA Audits The pharmaceutical industry faces constant scrutiny from regulatory bodies such as the FDA and EMA, and inspection readiness is…

Inspection readiness untested during FDA/EMA inspection – inspection playbook and preparation strategy

Preparing for FDA/EMA Inspections: A Comprehensive Playbook for Inspection Readiness Pharmaceutical manufacturers are regularly subject to inspections by regulatory bodies such as the FDA, EMA, and MHRA. Many times, the…

Illegible entries in controlled records during deviation investigation – ALCOA+ gap analysis

Managing Illegible Entries in Controlled Records During Deviation Investigations Illegible entries in controlled records can significantly impact the integrity of data during deviation investigations in pharmaceutical manufacturing. These inconsistencies can…